series-a
Stage
2018
Founded
1
Investors
About
Synklino is a biotechnology company developing first-in-class therapies to eliminate latent viral reservoirs in people with chronic viral infections, with an initial focus on Cytomegalovirus (CMV).
Explore Synklino's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.